Denis Drygin
CIK 1819692 · Chief Scientific Officer · last filed 2022-03-01
Denis Drygin is a Chief Scientific Officer who has filed 5 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing shows the insider bought $17.6K of RGLS on Mar 1, 2022. Across all open-market trades the lifetime net is +$23.0K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
5
$23.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc. (RGLS) Delisted | Chief Scientific Officer | 100,000 | $8.16 | $816.0K | $23.0K | 5 | 2022-03-01 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-03-01 | Regulus Therapeutics Inc. (RGLS) Delisted | Buy (P) | +76,686 | $17.6K | EDGAR |
| 2022-02-07 | Regulus Therapeutics Inc. (RGLS) Delisted | Buy (P) | +23,314 | $5.4K | EDGAR |
| 2022-01-26 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-05 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-05 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |